BioWorld Asia

Nov. 14, 2007

Antisense Pharma Gets $39.5M For Antisense Glioma Product

Antisense Pharma GmbH raised €27 million (US$39.5 million) in a third investment round funded solely by MIG AG, which also was the only investor in its €18 million funding round two years ago. (BioWorld International) Read More

Acambis Partners West Nile Vaccine In $80M Sanofi Deal

Novel Obesity Gene Plays A Role In Modifying DNA

Actelion Advances Clazosentan Into Phase III Vasospasm Study

Peptech Reinvents Itself As Arana, Shifts To Antibodies

Cerep Sells Hesperion To CRO Averion In €25M Deal

No Abstract Read More

Activists Strike At European Industry's Lobbying Power

Other News To Note

LSD Deal Brings Amicus $50M Now, $390M Later

As Big Pharma Model Falters, Biotech Rides To The Rescue

Today's news in brief

BioWorld

BioWorld briefs for Dec. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 24, 2024.

Illustration of neurons with Lewy bodies

Enhanced Cognition: Lewy body dementia phase II pumps stock

BioWorld

Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Lab glassware and antibodies art concept

Probing bidirectional cancer-autoimmune link can yield new targets

BioWorld Science

Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s...